BIO-TECHNE Corp vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? BIO-TECHNE Corp trades at $72.69 (market cap $11.37B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.29 (market cap $2.45B). The key difference: BIO-TECHNE Corp is far larger — about 4.6× Energy Fuels Inc Ordinary Shares (Canada)'s market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Energy Fuels Inc Ordinary Shares (Canada) pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| TECH | UUUU | |
|---|---|---|
Market Cap | $11.37B | $2.45B |
Volume | 2,420,565 | 7,967,898 |
Sector | Health | Energy |
52-Week High | $72.61 | $27.72 |
52-Week Low | $43.31 | $8.34 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $11.39B | $2.19B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.50, near its 52-week high of $72.70, with a slight daily decline of 0.08%. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.5 suggest premium pricing. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share is a key development. Earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026, and net income declined to $73.40 million in 2025 from $168 million in 2024.
The stock's outlook is supported by the pending acquisition, offering a near-term upside to the $73.00 buyout price. However, high valuation and earnings volatility pose risks. Analyst sentiment is balanced with 46% buy ratings, but no sell recommendations. Investors should weigh the acquisition premium against fundamental concerns like margin compression.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →